| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/13/2004 | US6677342 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure |
| 01/13/2004 | US6677340 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 01/13/2004 | US6677339 S-3-(4-(3,5-dichloropyrid-4-ylcarboxamido)phenyl)-2-(4,6-dimet hoxy-1,3,5-triazin-2-ylamino)propanoic acid for example; inhibit binding of alpha 4 integrins to their ligands, for treating immune or inflammatory disorders |
| 01/13/2004 | US6677338 Serotonin transport inhibitors |
| 01/13/2004 | US6677330 Acetylcholinesterase inhibitors; treating alzheimer*s disease, attention deficit, hyperactivity and brain disorders |
| 01/13/2004 | US6677319 Phosphatidylcholine as medication with protective effect large intestinal mucosa |
| 01/13/2004 | US6677309 Anthracycline derivatives |
| 01/13/2004 | US6677308 Integrin antagonists; antitumor, antimetastasis, anticarcinogenic agents; angiogenesis and restenosis inhibitors; osteoporosis |
| 01/13/2004 | US6677301 Epithelial cell proliferation stimulants; wound healing agents |
| 01/13/2004 | US6677145 Isolating a nucleotide sequence having specific sequence, constructing a vector consists of an isolated nucleotide sequence operably linked to a promoter, introducing the vector into host cell for expression of elongase enzyme |
| 01/13/2004 | US6677136 Glucagon antagonist domain, preferably having very little or no glucagon agonist activity, yeast-based screening phage display, rna- peptide screening, etc. attached to a vehicle, e.g., an fc domain, peg or dextran |
| 01/13/2004 | US6677133 Methods of reducing microbial resistance to drugs |
| 01/13/2004 | US6677126 Antibody for human translational regulator |
| 01/13/2004 | US6676985 Bovine lactation associated immunotropic protein (CD14), encoding gene and application in B cell activation |
| 01/13/2004 | US6676980 Method for preparing an olea europaea extract and method of use of the same |
| 01/13/2004 | US6676977 Pharmaceutical compositions and methods for reducing the appearance of cellulite |
| 01/13/2004 | US6676941 For inhibiting angiogenesis and induce tumor regression; cancer therapy |
| 01/13/2004 | US6676939 Methods of modulating IL-174 response |
| 01/13/2004 | US6676934 Antitumor agents; prevent or suppress glucose uptake; disrupt microtubules; induce apoptosis |
| 01/13/2004 | CA2280850C Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies |
| 01/13/2004 | CA2172726C A1 adenosine receptor antagonists |
| 01/13/2004 | CA2139731C 2-heterocyclic-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents |
| 01/13/2004 | CA2076664C Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists |
| 01/13/2004 | CA2000498C Osteogenic factors |
| 01/08/2004 | WO2004003545A1 Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers |
| 01/08/2004 | WO2004003510A2 Fluorescent dyes, energy transfer couples and methods |
| 01/08/2004 | WO2004003201A2 Antisense modulation of lrh1 expression |
| 01/08/2004 | WO2004003179A1 Differentiation modulating agents and uses therefor |
| 01/08/2004 | WO2004003166A2 Antibodies and uses thereof |
| 01/08/2004 | WO2004003000A2 1’-, 2'- and 3'- modified nucleoside derivatives for treating flaviviridae infections |
| 01/08/2004 | WO2004002999A2 Modified 2' and 3' -nucleoside produgs for treating flaviridae infections |
| 01/08/2004 | WO2004002983A2 Therapeutic piperazine derivatives useful for treating pain |
| 01/08/2004 | WO2004002978A1 Refreshment capable of stimulating movement of digestive tract |
| 01/08/2004 | WO2004002964A1 Diaminopyrimidinecarboxa mide derivative |
| 01/08/2004 | WO2004002963A1 Amide derivative |
| 01/08/2004 | WO2004002962A1 Novel benzimidazol-2-one derivatives and their use |
| 01/08/2004 | WO2004002961A1 Caspase inhibitors and uses thereof |
| 01/08/2004 | WO2004002959A1 Novel azasugar derivative and drug containing the same as the active ingredient |
| 01/08/2004 | WO2004002948A1 Amide compound and medicinal use thereof |
| 01/08/2004 | WO2004002944A1 Inhibitors of hcv ns5b polymerase |
| 01/08/2004 | WO2004002940A1 Inhibitors of hcv ns5b polymerase |
| 01/08/2004 | WO2004002939A2 Aminoalcohol derivatives |
| 01/08/2004 | WO2004002549A1 Use of organic compounds |
| 01/08/2004 | WO2004002535A1 Use of an npy y2 receptor antagonist for treating disorders related to angiogenesis |
| 01/08/2004 | WO2004002533A1 Stable liquid parenteral parecoxib formulation |
| 01/08/2004 | WO2004002531A1 Remedies for diseases caused by vascular contraction or dilation |
| 01/08/2004 | WO2004002530A1 Remedy for chronic disease |
| 01/08/2004 | WO2004002528A1 Compositions and methods for therapeutic treatment |
| 01/08/2004 | WO2004002526A1 Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas |
| 01/08/2004 | WO2004002525A1 Use of antibodies against flt-1 for the treatment of osteoporosis |
| 01/08/2004 | WO2004002524A1 Placental growth factor as a target for the treatment of osteoporosis |
| 01/08/2004 | WO2004002517A1 Diagnostics/preventives/re medies for respiratory diseases |
| 01/08/2004 | WO2004002516A1 Diagnostics/preventives/re medies for respiratory diseases |
| 01/08/2004 | WO2004002515A1 Diagnostics/preventives/remedies for respiratory diseases |
| 01/08/2004 | WO2004002514A1 Preventives/remedies for cancer |
| 01/08/2004 | WO2004002511A1 Anti-hiv agent |
| 01/08/2004 | WO2004002509A2 Use of casein peptides for treating hypertension |
| 01/08/2004 | WO2004002505A1 Compositions against inflammatory processes |
| 01/08/2004 | WO2004002501A1 Antiallergic agent, utilization thereof for reducing allergy and method of reducing allergy |
| 01/08/2004 | WO2004002493A1 Erythropoietin production potentiator |
| 01/08/2004 | WO2004002492A1 Use of vasopeptidase inhibitors in the treatment of nephropathy |
| 01/08/2004 | WO2004002485A1 Combination comprising a vasculostatic compound and an alkylating agent for the treatmemt of a tumor |
| 01/08/2004 | WO2004002484A1 Phosphodiesterase inhibitor |
| 01/08/2004 | WO2004002481A1 Aryl carbonyl derivatives as therapeutic agents |
| 01/08/2004 | WO2004002477A1 2-(phenyl)-2h-pyrazole-3-carboxylic acid-n-4-(thioxo-heterocyclyl)-phenyl-amide derivatives and corresponding imino-heterocyclyl derivatives and relates compounds for use as inhibitors of the coagulation factors xa and/or viia for treating thromboses |
| 01/08/2004 | WO2004002474A1 Drug composition for prevention or inhibition of advance of diabetic complication |
| 01/08/2004 | WO2004002473A1 Drug composition for blood sugar control |
| 01/08/2004 | WO2004002466A1 Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant |
| 01/08/2004 | WO2004002465A1 DRUG COMPOSITION CONTAINING NF-κB INHIBITOR |
| 01/08/2004 | WO2004002462A2 Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder |
| 01/08/2004 | WO2004002461A2 Combination of pde5 inhibitors with angiotensin ii receptor antagonists |
| 01/08/2004 | WO2004002459A1 Hollow nanoparticle having modified cysteine residue and drug with the use thereof |
| 01/08/2004 | WO2004002455A1 Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system |
| 01/08/2004 | WO2004002433A1 Synergistic interaction of abacavir and alovudine |
| 01/08/2004 | WO2004002424A2 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| 01/08/2004 | WO2004002422A2 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| 01/08/2004 | WO2004002420A2 Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use |
| 01/08/2004 | WO2004002418A2 Compositions and methods comprising protein activated receptor antagonists |
| 01/08/2004 | WO2004002402A2 Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
| 01/08/2004 | WO2004002239A2 Purified amylase inhibitor and novel process for obtaining the same |
| 01/08/2004 | WO2003090912A9 Pyrrolo-triazine aniline compounds useful as kinase inhibitors |
| 01/08/2004 | WO2003087174A3 Carbocyclic and oxacarbocyclic fumaric acid oligomers |
| 01/08/2004 | WO2003087139A3 Treatment of gastroparesis |
| 01/08/2004 | WO2003087088A3 (condensed) pyrimidone and (condensed) pyridone compounds, processes for their preparation, and pharmaceutical compositions containing them |
| 01/08/2004 | WO2003086315A3 Tyrosine kinase inhibitors |
| 01/08/2004 | WO2003086279A3 Inhibitors of akt activity |
| 01/08/2004 | WO2003084928A8 Alpha, omega-dicarboximide derivatives as useful uro-selective α1α adrenoceptor blockers |
| 01/08/2004 | WO2003076445A3 Microtubule stabilizing compounds |
| 01/08/2004 | WO2003076429A3 Azepane derivatives and their use as atk1 inhibitors |
| 01/08/2004 | WO2003075850A3 Methods for alzheimer's disease treatment and cognitive enhancement |
| 01/08/2004 | WO2003075844A3 Compositions and methods for preventing and treating cancer via modulating ube1l, isg15 and/or ubp43 |
| 01/08/2004 | WO2003070166A3 Novel tyloindicines and related processes, pharmaceutical compositions and methods |
| 01/08/2004 | WO2003068812A3 Immune-modulating peptide made of s. aureus enterotoxin b |
| 01/08/2004 | WO2003067262A3 Methods and compositions involving the hsp90 activator aha1 |
| 01/08/2004 | WO2003066205A3 Microcapsules having high carotenoid content |
| 01/08/2004 | WO2003064378A3 Novel compounds that inhibit factor xa activity |
| 01/08/2004 | WO2003061604A3 Novel alkyl/aryl hydroxy or keto thiepines. |
| 01/08/2004 | WO2003054194A3 Modified tridegins, production and use thereof as transglutaminase inhibitors |
| 01/08/2004 | WO2003047618A3 Immunotherapeutic methods and systems |
| 01/08/2004 | WO2003045965A3 Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same |